Group of subjects | Sum of subjects with indicated numbers of adverse signs as percent of total number per group | ||||||||
---|---|---|---|---|---|---|---|---|---|
Line | Name1) | Total number | Numbers of multiple adverse signs | Serum PCB (ng/g lipid) 5% – 95% | |||||
0+1 | 2+3 | 4+5 | 6+7 | 8+9 | 10+11 | ||||
1 | POLL all | 1008 | 12.4 | 32.5 | 29.6 | 19.3 | 5.3 | 0.7 | 672 – 9103 |
2 | POLL all M | 432 | 9.9 | 32.4 | 29.3 | 21.7 | 5.5 | 0.9 | 736 – 11745 |
3 | POLL all F | 576 | 14.2 | 32.6 | 30.1 | 17.5 | 5.2 | 3.5 | 632 – 7075 |
4 | POLL yng M | 133 | 15.1A | 40.7C | 30.8 | 11.3E | 2.2A | ----- | 545 – 5687 |
5 | POLL old M | 299 | 7.7A | 28.7C | 28.7 | 26.4E | 6.9A | 1.3 | 1129 – 13801 |
6 | POLL yng F | 157 | 21.1C | 40.1D | 26.1 | 9.4C | 1.9B | ----- | 507 – 4141 |
7 | POLL old F | 419 | 11.7C | 29.6D | 32.3 | 20.5C | 6.4B | ----- | 818 – 8430 |
8 | BCGR all | 1038 | 27.2 | 37.3 | 27.1 | 8.1 | 2.1 | ----- | 354 – 1698 |
9 | BCGR all M | 402 | 21.9 | 40.8 | 27.6 | 7.9 | 1.4 | ----- | 430 – 1992 |
10 | BCGR all F | 635 | 28.9 | 34.9 | 25.3 | 8.1 | 0.3 | ----- | 321 – 1380 |
11 | BCGR yng M | 116 | 38.2E | 47.8A | 13.1E | 2.6A | ----- | ----- | 343 – 1129 |
12 | BCGR old M | 286 | 15.7E | 38.1A | 33.9E | 9.8A | 2.1 | ----- | 587 – 2467 |
13 | BCGR yng F | 172 | 46.2F | 35.8 | 15.1F | 2.9C | ----- | ----- | 251 – 1194 |
14 | BCGR old F | 463 | 22.5F | 34.8 | 28.9F | 10.4C | 3.4 | ----- | 369 – 1578 |